Tyrphostin AG 1296

Names

[ Name ]:
Tyrphostin AG 1296

[Synonym ]:
6,7-Dimethoxy-2-phenylquinoxaline
Quinoxaline, 6,7-dimethoxy-2-phenyl-
Quinoxaline,6,7-dimethoxy-2-phenyl
2-phenyl-6,7-dimethoxyquinoxaline
Tyrphostin AG-1296
2-phenyl-6,7-dimetoxyquinoxaline
MFCD00270913
6,7-Dimethoxy-3-phenylquinoxaline

Biological Activity

[Description]:

Tyrphostin AG1296 is a potent and selective inhibitor of platelet-derived growth factor receptor (PDGFR), with an IC50 of 0.8 μM. Tyrphostin AG1296 inhibits signaling of human PDGF α- and β-receptors as well as of the related stem cell factor receptor (c-Kit). Tyrphostin AG1296 is also a potent inhibitor of FLT3, with an IC50 in the micromolar range[1][2][3].

[Related Catalog]:

Signaling Pathways >> Apoptosis >> Apoptosis

Research Areas >> Cancer

Research Areas >> Cardiovascular Disease

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> PDGFR

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FLT3

Research Areas >> Inflammation/Immunology

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> c-Kit

[Target]

PDGFRα

PDGFRβ

[In Vitro]

Tyrphostin AG1296 (0.625-20 μM; 72 h) suppresses viability of PLX4032-resistant melanoma cells[4]. Tyrphostin AG1296 (2.5-20 μM; 48 h) induces apoptosis of A375R cells[4]. Tyrphostin AG1296 (5 and 20 μM; 2 h) inhibits PDGFR phosphorylation in A375R cells[4]. Tyrphostin AG1296 (0.0625-1 μM; 8 h) inhibits migration of A375R cells[4]. Cell Viability Assay[4] Cell Line: PLX4032-resistant cell lines (A375R and SK-MEL-5R) Concentration: 0.625, 1.25, 5, 20 μM Incubation Time: 72 h Result: Reduced the viability of both PLX4032-sensitive and PLX4032-resistant cell lines. Apoptosis Analysis[4] Cell Line: A375R cells Concentration: 2.5, 5, 10, 20 μM Incubation Time: 48 h Result: Induced dramatic apoptosis in A375R cells. Western Blot Analysis[4] Cell Line: A375R cells Concentration: 5, 20 μM Incubation Time: 2 h Result: Inhibited phosphorylation of both PDGFR-α and PDGFR-β.

[In Vivo]

Tyrphostin AG1296 (40 and 80 mg/kg; i.p. daily for two weeks) suppresses A375R tumor growth in vivo[4]. Tyrphostin AG1296 (2 mg/kg; i.p. every other day for 3 weeks) inhibits the atherosclerotic plaque progression and enhances plaque stability by inhibiting inflammatory responses, reducing the expression of matrix metalloproteinases and promoting macrophages from proinflammatory phenotype to anti-inflammatory phenotype[5]. Animal Model: Nud/nud mice are injected with A375R cells[4] Dosage: 40, 80 mg/kg Administration: I.p. daily for two weeks Result: Led to an intermediate level of tumor growth suppression at dose of 40 mg/kg, and significant inhibition of A375R tumor growth at dose of 80 mg/kg. Well tolerated by healthy mice without significant signs of overt toxicity or weight loss.

[References]

[1]. Gazit A, etm, al. Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins. Comparative Study J Med Chem. 1996 May 24; 39(11): 2170-7.

[2]. Kovalenko M, et, al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 1994 Dec 1; 54(23): 6106-14.

[3]. Tse KF, et, al. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia. 2002 Oct; 16(10): 2027-36.

[4]. Li Y, et, al. Tyrphostin AG1296, a platelet-derived growth factor receptor inhibitor, induces apoptosis, and reduces viability and migration of PLX4032-resistant melanoma cells. Onco Targets Ther. 2015 May 14; 8: 1043-51.

[5]. Dong M, et, al. AG1296 enhances plaque stability via inhibiting inflammatory responses and decreasing MMP-2 and MMP-9 expression in ApoE-/- mice. Biochem Biophys Res Commun. 2017 Aug 5;489(4):426-431.